Glenmark achieves positive results for anti-diarrhoea molecule

08 Feb 2011 Evaluate

Drug firm Glenmark Pharmaceuticals has achieved positive results in human trials for its new drug molecule Crofelemer, which is aimed at treating diarrhea in adults.Resolution of diarrhea was significantly higher in human subjects, who were given Crofelemer compared to those who were not in a multi-centre trial. Crofelemer will potentially be the first new chemical entity (NCE) to be launched by the organization.

Glenmark will accelerate the development of Crofelemer in the acute indications, including pediatric diarrhea where several million individuals are affected in the geographies that we operate in. Crofelemer is licensed to the company from US-based Napo Pharmaceuticals. In November 2010, Glenmark along with Napo and Salix Pharmaceuticals, had announced the successful completion of phase III trials with Crofelemer for the treatment of diarrhea in patients with HIV in the US.

Glenmark has the exclusive license to develop, commercialise and distribute Crofelemer in 140 emerging countries for indications related to HIV, use in acute diarrhea, including supply to NGOs for delivery within these countries. Glenmark and Salix have also entered into a commercial supply agreement for Crofelemer active pharmaceutical ingredient,crackcrack

Glenmark Pharma Share Price

1178.00 17.25 (1.49%)
03-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1453.25
Dr. Reddys Lab 5792.95
Cipla 1459.85
Zydus Lifesciences 1032.25
Lupin 1583.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.